Literature DB >> 28237625

Selective sensitization of human neutrophils to LukGH mediated cytotoxicity by Staphylococcus aureus and IL-8.

Philipp Janesch1, Harald Rouha1, Susanne Weber1, Stefan Malafa1, Karin Gross1, Barbara Maierhofer1, Adriana Badarau1, Zehra C Visram1, Lukas Stulik1, Eszter Nagy2.   

Abstract

OBJECTIVES: Staphylococcus aureus produces up to five bi-component leukocidins - LukSF-PV, gamma-hemolysins AB and CB, LukGH (LukAB) and LukED - to evade innate immunity by lysing phagocytic cells. Species specificity of these leukocidins limits the relevance of animal models, therefore we assessed their individual contribution using human neutrophils.
METHODS: Human polymorphonuclear leukocytes (PMNs) were activated with stimuli relevant during bacterial infections and sensitivity to recombinant leukocidins was measured in cell-viability assays. Leukocidin receptor expression was quantified by flow cytometry.
RESULTS: We observed greatly variable sensitivities of different PMN preparations towards LukGH. Activation of PMNs by lipopolysaccharide (LPS) or S. aureus culture supernatant (CS) lacking all leukocidins resulted in higher surface expression of CD11b, the LukGH receptor, and greatly enhanced the sensitivity towards LukGH, eliminating the variability observed with unstimulated cells. In contrast, CS induced a decrease in sensitivity of PMNs to the other four leukocidins and reduced surface staining for their cognate receptors (CXCR1, CXCR2, C5aR, C5L2). Delta-toxin and peptidoglycan mimicked the effect of CS. Moreover, IL-8, an important cytokine in neutrophil activation, also selectively increased LukGH sensitivity. Deletion of lukGH, but not other leukocidin genes, prevented PMN killing upon infection with USA300 CA-MRSA.
CONCLUSION: Inflammatory signals enhance the susceptibility of human PMNs to lysis by LukGH rendering this toxin dominant among the S. aureus leukocidins in vitro.
Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  CD11b expression; Immune evasion; Leukocidin; LukGH/LukAB; PMN activation; Staphylococcus aureus

Mesh:

Substances:

Year:  2017        PMID: 28237625     DOI: 10.1016/j.jinf.2017.02.004

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  8 in total

1.  The Concern for Vancomycin Failure in the Treatment of Pediatric Staphylococcus aureus Disease.

Authors:  Isaac P Thomsen
Journal:  Clin Infect Dis       Date:  2019-01-18       Impact factor: 9.079

Review 2.  Targeting fundamental pathways to disrupt Staphylococcus aureus survival: clinical implications of recent discoveries.

Authors:  Isaac P Thomsen; George Y Liu
Journal:  JCI Insight       Date:  2018-03-08

3.  Commercial Intravenous Immunoglobulin Preparations Contain Functional Neutralizing Antibodies against the Staphylococcus aureus Leukocidin LukAB (LukGH).

Authors:  James B Wood; Lauren S Jones; Nicole R Soper; Meera Nagarsheth; C Buddy Creech; Isaac P Thomsen
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies.

Authors:  Harald Rouha; Susanne Weber; Philipp Janesch; Barbara Maierhofer; Karin Gross; Ivana Dolezilkova; Irina Mirkina; Zehra C Visram; Stefan Malafa; Lukas Stulik; Adriana Badarau; Eszter Nagy
Journal:  Virulence       Date:  2017-12-26       Impact factor: 5.882

5.  Antibody-based intervention against the pore-forming toxins of Staphylococcus aureus.

Authors:  Isaac P Thomsen
Journal:  Virulence       Date:  2018-12-31       Impact factor: 5.882

6.  Associations of pathogen-specific and host-specific characteristics with disease outcome in patients with Staphylococcus aureus bacteremic pneumonia.

Authors:  Batu K Sharma-Kuinkel; Christine Tkaczyk; Jessica Bonnell; Li Yu; Andrey Tovchigrechko; David E Tabor; Lawrence P Park; Felicia Ruffin; Mark T Esser; Bret R Sellman; Vance G Fowler; Alexey Ruzin
Journal:  Clin Transl Immunology       Date:  2019-07-19

7.  Molecular mechanism of leukocidin GH-integrin CD11b/CD18 recognition and species specificity.

Authors:  Nikolina Trstenjak; Dalibor Milić; Melissa A Graewert; Harald Rouha; Dmitri Svergun; Kristina Djinović-Carugo; Eszter Nagy; Adriana Badarau
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-18       Impact factor: 11.205

8.  Exploiting species specificity to understand the tropism of a human-specific toxin.

Authors:  K M Boguslawski; A N McKeown; C J Day; K A Lacey; K Tam; N Vozhilla; S Y Kim; M P Jennings; S B Koralov; N C Elde; V J Torres
Journal:  Sci Adv       Date:  2020-03-11       Impact factor: 14.136

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.